Second-Generation Antiandrogens Linked to Falls, Cognitive Toxicity in Prostate Cancer Patients
Prostate cancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity.
Diagnosis & Disease Information
In Advanced Prostate Cancer, Statin Use With Androgen Ablation Ups Survival
Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.
Abiraterone and Enzalutamide Raise Metabolic, Cardiovascular Adverse Event Risks
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
ADT + Pelvic Lymph Node Radiation Improves Prostate Cancer Outcomes
Five-year freedom from progression rate higher for those receiving short-term ADT and PLNRT in addition to salvage PBRT.
Statins May Benefit Patients Receiving ADT for Relapsed Prostate Cancer
In a study, statin use was associated with a 36% decreased risk for death among men initiating androgen deprivation therapy for recurrent prostate cancer following primary or salvage radiation therapy.
Darolutamide Prolongs Overall Survival in nmCRPC
Darolutamide also improved secondary endpoints, including the time to pain progression, cytotoxic chemotherapy, and first symptomatic skeletal event.
Oral Antiandrogens Found to Increase Dementia Risk
In a study, only androgen deprivation therapy with oral antiandrogens were associated with an increased risk for dementia and Alzheimer disease.
Priorities in Prostate Cancer Care During the Pandemic
The authors of a new review discuss priorities, adjustments, and tailored approaches to prostate cancer management during the COVID-19 pandemic.
ADT Use Enables Delay in Prostate Cancer Radiation Therapy
Radiation therapy for higher-risk prostate cancer can be delayed for up to 6 months following initiation of hormonal therapy without incurring a greater mortality risk, a finding that has implications for patient care during the COVID-19 pandemic.
ADT May Decrease Risk of COVID-19 in Men With Prostate Cancer, Study Finds
TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...